 | ||||||||||||||||||||||||||||||||||||
 |
PASSION FOR IDEAS |
|||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
OncoEthixOncoEthix is a biopharmaceutical start up located in Lausanne, Switzerland, and exclusively dedicated to the development of novel drug candidates for oncological indications. OncoEthix thus intends to in-license and to develop until proof-of-concept in human a portfolio of 3 to 5 agents, either small molecules or biologicals, before establishing partnerships with larger companies. The first compound of OncoEthix a small molecule inhibiting angiogenesis (blood vessel formation) within the tumor through a novel mechanism.
|
|
|
|
|||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
| partner of the European Tech Tour |  |
"The partners have been very supportive of our approach and stepped in to add value when needed. I would strongly recommend them as investors." Didier Cowling, Founder and CEO, Kuros Biosurgery AG |
||||||||||||||||||||||||||||||||||
current news
Olivier Valdenaire
Sven Lingjaerde